Clinical Trial Results:
COVID-19: A Phase 3, open-label, parallel group, multicenter clinical study to evaluate the safety, reactogenicity, and immunogenicity of the investigational SARS-CoV-2 mRNA vaccine CVnCoV in participants 45 years or older with either a solid tumor or hematologic malignant disease who are receiving or scheduled to receive systemic anticancer therapy (independent of intent)
Summary
|
|
EudraCT number |
2021-001735-10 |
Trial protocol |
BE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
23 May 2022
|
First version publication date |
23 May 2022
|
Other versions |
|
Summary report(s) |
Withdrawn statement |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.